Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Trinity Biotech (TRIB) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Trinity Biotech (TRIB) over the last 17 years, with Q2 2025 value amounting to $1.5 million.

  • Trinity Biotech's Cash & Equivalents fell 7092.35% to $1.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $1.5 million, marking a year-over-year decrease of 7092.35%. This contributed to the annual value of $5.2 million for FY2024, which is 2145.03% down from last year.
  • Per Trinity Biotech's latest filing, its Cash & Equivalents stood at $1.5 million for Q2 2025, which was down 7092.35% from $5.2 million recorded in Q4 2024.
  • Trinity Biotech's Cash & Equivalents' 5-year high stood at $28.6 million during Q2 2021, with a 5-year trough of $1.5 million in Q2 2025.
  • In the last 5 years, Trinity Biotech's Cash & Equivalents had a median value of $20.1 million in 2021 and averaged $16.8 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 8380.22% in 2021, then plummeted by 7465.23% in 2022.
  • Quarter analysis of 5 years shows Trinity Biotech's Cash & Equivalents stood at $25.9 million in 2021, then changed by 0.0% to $25.9 million in 2022, then crashed by 74.61% to $6.6 million in 2023, then dropped by 21.45% to $5.2 million in 2024, then crashed by 70.08% to $1.5 million in 2025.
  • Its last three reported values are $1.5 million in Q2 2025, $5.2 million for Q4 2024, and $5.3 million during Q2 2024.